Pharmaceuticals North America

North America Microbiome Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

North America Microbiome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Product, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

North America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $360.1 Mn Placeholder estimate
Estimate 2025 $463.5 Mn 45.7% of the global market
Projected 2034 $4.49 Bn 868.7% Adds $4.03 Bn over 9 forecast years
CAGR 2025–2034 28.7% Faster than 97% of 180 Pharmaceuticals markets here
Key players 5
  • North America is 45.71% of the global market.
  • Among regions, the largest is North America (this report) at $463.5 Mn.
  • Fastest growing: APAC at 31.3% a year.
  • North America ranks 1st of 6 by size among regions.

Market size projection

North America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$4.03 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Microbiome Therapeutics Market market size by year, North America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $360.1 Mn — —
2025 (base) $463.5 Mn +$103.3 Mn —
2026 (forecast) $596.5 Mn +$133.0 Mn +28.7%
2027 (forecast) $767.6 Mn +$171.2 Mn +65.6%
2028 (forecast) $988.0 Mn +$220.3 Mn +113.2%
2029 (forecast) $1.27 Bn +$283.5 Mn +174.4%
2030 (forecast) $1.64 Bn +$364.9 Mn +253.1%
2031 (forecast) $2.11 Bn +$469.7 Mn +354.4%
2032 (forecast) $2.71 Bn +$604.4 Mn +484.9%
2033 (forecast) $3.49 Bn +$777.9 Mn +652.7%
2034 (forecast) $4.49 Bn +$1.00 Bn +868.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

North America Microbiome Therapeutics Market Analysis at a glance
Market size, 2025$463.5 Mn placeholder estimate
Forecast, 2034$4.49 Bn placeholder estimate
Growth (CAGR), 2025–203428.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, indication and end user (see all)
Key playersSeres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, MaaT Pharma, Nestle (see all)
Active clinical trials335 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The North America Microbiome Therapeutics Market Analysis Executive Summary

Microbiome therapeutics use live bacteria or their products as medicines, for infections, bowel disease and other conditions.

Key segments of the microbiome Therapeutics market include product (Fecal Microbiota Products, Live Biotherapeutics and Microbiome Modulators) and indication (C. difficile, IBD and Oncology).

Bar chart: North America Microbiome Therapeutics market size, 2024–2034, placeholder estimates. $360.1 Mn in 2024, $463.5 Mn in 2025 and $4.49 Bn in 2034, 28.7% CAGR.
North America Microbiome Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

North America Microbiome Therapeutics Market Dynamics

Market Growth Drivers

Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the microbiome Therapeutics market.

Opportunity

Microbiome-based treatments, earlier testing and digital gut-health programmes give the microbiome Therapeutics market room to grow.

Market Restraints

Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the microbiome Therapeutics market.

Competitive Landscape for Microbiome Therapeutics Market in North America

The microbiome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Microbiome Therapeutics Market in North America

Microbiome Therapeutics in North America: rules, payment and research

In the countries we cover here, medicines are approved by Health Canada (Canada)⁠[1] and FDA (US)⁠[2]. How care is paid for in these countries: provincial health insurance (Canada)⁠[3] and Medicare and Medicaid (US)⁠[4]. ClinicalTrials.gov lists 335 studies on Microbiome Therapeutics that are recruiting, active or about to start in North America.⁠[5]

[1] Health Canada. Checked 14 Nov 2026.

[2] US Food and Drug Administration. Checked 14 Nov 2026.

[3] Health Canada. Checked 14 Nov 2026.

[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[5] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for microbiome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Microbiome Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Microbiome Therapeutics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Microbiome Therapeutics market in North America?
Placeholder estimate: about $463.5 Mn in 2025, rising to about $4.49 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Microbiome Therapeutics market in North America growing?
Placeholder estimate: about 28.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Microbiome Therapeutics market report cover?
The report splits the market by product (Fecal Microbiota Products, Live Biotherapeutics, Microbiome Modulators), indication (C. difficile, IBD, Oncology, Metabolic Disease) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Microbiome Therapeutics market?
Key players include Seres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, MaaT Pharma and Nestle.
What is driving the Microbiome Therapeutics market?
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the microbiome Therapeutics market.
How many clinical trials on Microbiome Therapeutics are running in North America?
335 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on Microbiome Therapeutics?
PubMed lists 151 papers on Microbiome Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in North America

See all

Related on gut health and biologics and biosimilars

See the topic